KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Gross Profit (2016 - 2025)

Historic Gross Profit for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $299.0 million.

  • Halozyme Therapeutics' Gross Profit rose 2425.18% to $299.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 3511.63%. This contributed to the annual value of $855.9 million for FY2024, which is 3438.81% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Gross Profit of $299.0 million as of Q3 2025, which was up 2425.18% from $279.4 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Gross Profit registered a high of $299.0 million during Q3 2025, and its lowest value of $70.8 million during Q1 2021.
  • Moreover, its 5-year median value for Gross Profit was $161.7 million (2022), whereas its average is $166.9 million.
  • Examining YoY changes over the last 5 years, Halozyme Therapeutics' Gross Profit showed a top increase of 26184.9% in 2021 and a maximum decrease of 1573.39% in 2021.
  • Over the past 5 years, Halozyme Therapeutics' Gross Profit (Quarter) stood at $80.4 million in 2021, then skyrocketed by 73.32% to $139.4 million in 2022, then rose by 27.53% to $177.7 million in 2023, then surged by 44.0% to $256.0 million in 2024, then rose by 16.83% to $299.0 million in 2025.
  • Its Gross Profit stands at $299.0 million for Q3 2025, versus $279.4 million for Q2 2025 and $216.5 million for Q1 2025.